# Division 14 — Clinical Trials & Quantum Health Solutions

**AutoQMS / QM2ARL · Division 14**
**Standards:** ICH-GCP E6(R2) · FDA 21 CFR Parts 11/50/56/312/812 · ISO 14155:2020
**Program:** SkinProto Protocol Matrix — skin damage & wound care

---

## ⚠️ Scope & disclaimer (read first)

Division 14 provides **regulatory-readiness and protocol-documentation decision
support**. It is **NOT**:

- medical advice, a diagnosis, or a treatment recommendation;
- a medical device or a therapeutic/efficacy claim;
- a substitute for an **IRB/IEC**, the **FDA/EMA**, a **sponsor**, a qualified
  **clinical investigator**, a **biostatistician**, or any **licensed medical
  professional**.

"Quantum" refers to the QM2ARL quantum-kernel **analysis** stack (the same
backend ladder as the rest of the platform), **not** a medical treatment. **No
protocol may enroll a human subject without independent IRB approval and
applicable regulatory authorization.**

---

## What it is

The clinical analogue of Division 12 (SPE-PRMS reserves) and Division 13
(NI 43-101 minerals): **8 AI auditor agents**, each owning one clinical-trial
regulatory domain, that score a protocol's documentation readiness and gate it
against critical safety/ethics thresholds — exactly the same engine, applied to
Good Clinical Practice.

### The 8 agents (GCP domains)

| # | Domain | Role |
|---|---|---|
| 0 | `protocol_design_endpoints` | Clinical Scientist — design, objectives & endpoints (ICH E6/E8) |
| 1 | `preclinical_mechanism` | Translational Scientist — mechanism, preclinical tox & efficacy |
| 2 | `cmc_formulation_encapsulation` | CMC Lead — GMP manufacturing, formulation & **encapsulation** quality |
| 3 | `safety_pharmacovigilance` | Medical Monitor — AE/SAE, DSMB, **oncology/carcinogenicity safety** |
| 4 | `irb_ethics_consent` | Ethics/Reg Affairs — IRB/IEC, informed consent (21 CFR 50/56) |
| 5 | `data_integrity_part11` | Data Manager — 21 CFR Part 11, ALCOA+, EDC |
| 6 | `statistical_efficacy` | Biostatistician — SAP, powering, efficacy endpoints |
| 7 | `regulatory_submission_audit` | Regulatory Lead — IND/IDE, ISO 14155, submission readiness |

**Critical gate domains** (a gap here = automatic HALT, no enrollment):
`safety_pharmacovigilance`, `irb_ethics_consent`, `data_integrity_part11`.

---

## The SkinProto Protocol Matrix

`src/quantum_health/skinproto.py`. A structured protocol scaffold organizing the
program's four science pillars into an ICH-GCP-shaped synopsis. Each pillar is
scored as an **evidence level [0,1]** from inputs the team supplies (the module
does not generate biological evidence or make claims):

| Pillar | What it covers |
|---|---|
| **methylation** | DNA-methylation biomarker panel for healing-response stratification & oncogenic-risk monitoring |
| **encapsulation** | Delivery system (nano/liposomal/hydrogel) for topical wound delivery; release kinetics, stability, GMP CMC |
| **cross_matrix** | Extracellular-matrix / cross-linked scaffold for tissue regeneration & re-epithelialization |
| **oncology_safety** | Carcinogenicity / genotoxicity / oncogenic-risk safety **gate** (skin-malignancy relevance) |

The matrix maps pillar evidence + protocol completeness to the 8 Division 14
domain readiness scores, which the clinical AI audit then combines with the
trained agents (`combined = min(trained, supplied)`).

---

## Run it

```python
from src.quantum_health import evaluate_protocol

out = evaluate_protocol({
    "indication": "Diabetic foot ulcer (chronic wound)",
    "phase": "phase_1",
    "methylation": {"biomarker_panel_validated": 0.7, "assay_qaqc": 0.7, "reference_cohort_strength": 0.6},
    "encapsulation": {"formulation_characterized": 0.7, "release_kinetics_defined": 0.6,
                       "gmp_process_readiness": 0.5, "stability_data": 0.5},
    "cross_matrix": {"scaffold_biocompatibility": 0.7, "crosslink_characterization": 0.6,
                      "regeneration_evidence": 0.6},
    "oncology_safety": {"carcinogenicity_assessed": 0.6, "genotoxicity_data": 0.6,
                         "oncogenic_risk_controlled": 0.6},
    "protocol": {"synopsis_defined": 0.7, "objectives_endpoints_defined": 0.7,
                  "inclusion_exclusion_defined": 0.6, "sample_size_justified": 0.5},
})
print(out["clinical_audit"]["audit_gate_passed"], out["matrix"]["protocol_completeness"])
```

## Train the agents

```bash
python simulations/compliance_audit.py configs/compliance_clinical_trials.yaml
# → results/autoqms_clinical_trials_training_summary.json
```

---

## How it connects to the platform

- **AutoQMS** — Division 14 sits alongside Divisions 10–13 as a compliance preset.
- **Omni-Dimensional Ledger** — `evaluate_protocol(..., record_resonance=True)`
  feeds clinical readiness into the ODL **Health** dimension, so the clinical
  program contributes to platform-wide System Resonance.
- **DragonSeal** — protocol/audit packages can be sealed like any controlled doc.
- **Quantum kernel** — the same VQC/BlueQubit analysis stack used across QM2ARL.

---

## Honest status

| Item | Status |
|---|---|
| 8-agent GCP compliance preset + training | OPERATIONAL |
| SkinProto Protocol Matrix scaffold + readiness scoring | OPERATIONAL |
| Division 14 clinical AI audit + critical-domain gating | OPERATIONAL |
| Biological efficacy / safety evidence | **Supplied by the team — not generated here** |
| Any therapeutic claim | **None made — out of scope** |
| Human enrollment | **Requires IRB approval + regulatory authorization** |
